OSRH News & Events

In a shareholder letter, CEO Peter Hwang said, in part, "Over the past year, we have continued to strengthen our position as a biomedical holding company with a growing portfolio of innovative businesses spanning oncology, regenerative medicine, medical devices, and digital health. We are seeing increasing external validation of the technologies and platforms being developed by our subsidiaries. Vaximm recently executed a definitive licensing agreement for the VXM01 immunotherapy platform, one of the most significant transactions in the Company's history. At Woori IO, development activities and strategic engagements involving global industry participants, including Samsung, continue to advance our noninvasive glucose monitoring platform. Across our portfolio, we are focused on transforming scientific innovation into commercial opportunities and long-term shareholder value. As a holding company, our responsibility is to continually evaluate how best to unlock the value of our underlying businesses for the benefit of shareholders. Public markets have repeatedly demonstrated that significant value can be created through thoughtful capital allocation, strategic partnerships, subsidiary monetizations, spin-offs, and other corporate actions that allow investors to participate more directly in the success of underlying assets. While we are not announcing any specific transaction at this time, I can assure shareholders that we are evaluating a full range of tools available to publicly listed Hub-and-Spoke biotech companies and are committed to pursuing opportunities that we believe will benefit our investors. We continue to work closely with Nasdaq, our advisors, and industry experts regarding our minimum bid price compliance process. Maintaining a Nasdaq listing remains an important objective, and we are evaluating pathways to achieve compliance while preserving and enhancing long-term shareholder value...The next chapter of OSRH will not be defined by a compliance deadline or short-term considerations such as the next quarter or month, but by its ability to translate scientific innovation into enduring shareholder value. We remain confident in our portfolio, our partners, and the opportunities before us, and we appreciate the continued trust and support of our shareholders as we execute our strategy."

OSR Holdings announced it has entered into a definitive Asset Purchase Agreement with VAXIMM AG to acquire the full global intellectual property portfolio and related assets for an aggregate purchase price of $30M. The acquisition follows OSRH's previously announced definitive global exclusive license agreement with BCM Europe for VXM01, which includes up to $815M in milestone payments tied to the development and commercialization of the program.

OSR Holdings entered into a definitive global exclusive license agreement with BCM Europe for the development, commercialization, and potential sublicensing of VXM01, its Phase 3-ready oral immunotherapy targeting VEGFR-2. The Agreement builds on the previously disclosed binding term sheet and establishes a structured framework to advance VXM01, with alignment across OSRH, its largest shareholder BCME, and public shareholders. BCME receives an exclusive global license to develop, manufacture, commercialize, and sublicense VXM01. OSRH to receive up to $815M in milestone payments tied to clinical, regulatory, and commercial achievements. OSRH to acquire full VXM01 IP from Vaximm AG under a $30M asset purchase agreement. OSRH to receive 100% of downstream royalties after BCME recovers its investment and preferred return. BCME and affiliates pledge 100% of their OSRH shares as collateral for milestone obligations; Governing Law: Switzerland. BCME is the Company's largest shareholder. Accordingly, the Agreement constitutes a related party transaction and was approved by the Board, including independent directors, following consideration of an independent fairness opinion provided by Avance Life Sciences. Under a separate Pledge Agreement, BCME and affiliates have pledged their entire unencumbered shareholding in OSRH, representing approximately 29.7% as of the signing date, as collateral for the performance of milestone payment obligations of up to $815M. BCME will actively support development of VXM01 and at the same time engage leading global pharmaceutical partners to secure a sublicensing transaction. With economic returns dependent on downstream monetization and its entire OSRH stake pledged as collateral, BCME is structurally incentivized to advance VXM01 and execute a competitive partnering process focused on maximizing value for OSRH shareholders. The Agreement also includes a put option under which OSRH may require BCME to purchase up to $15M of OSRH common stock at a price of $10.00 per share, exercisable no earlier than six months following the effective date.